We are live on ! Find out more
CLGN icon

CollPlant Biotechnologies
CLGN

15 hedge funds and large institutions have $24.4M invested in CollPlant Biotechnologies in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

150% more funds holding

Funds holding: 6 → 15 (+9)

138% more capital invested

Capital invested by funds: $10.2M → $24.4M (+$14.1M)

0.36% more ownership

Funds ownership: 1.47% → 1.83% (+0.36%)

Holders
15
Holders Change
+9
Holders Change %
+150%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FA
Friess Associates
Delaware
+$3.77M
2
IMOV
Investment Management of Virginia
Virginia
+$3.7M
3
SDJVC
St. Denis J. Villere & Co
Louisiana
+$2.33M
4
BFEC
Benjamin F. Edwards & Company
Missouri
+$834K
5
Brown Advisory
Brown Advisory
Maryland
+$824K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$126K

CLGN Hedge Fund Activity: Q1 2021 in Review

15 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q1 2021, worth a combined $24.4M — up 138% from $10.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CLGN positions and 1 closed out — a net gain of 9 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Friess Associates, opening a new position worth an estimated $3.77M. The largest seller was Citadel Advisors, exiting entirely with an estimated $126K sold.

  • 15 institutional investors held CollPlant Biotechnologies (CLGN) as of Q1 2021, up from 6 in Q4 2020.
  • Funds reported $24.4M of CollPlant Biotechnologies stock for Q1 2021, up 138% quarter-over-quarter.
  • 10 funds opened new CollPlant Biotechnologies positions in Q1 2021 and 1 closed out, a net change of +9 holders.
  • The largest CollPlant Biotechnologies buyer in Q1 2021 was Friess Associates, an estimated $3.77M added.
  • The largest CollPlant Biotechnologies seller in Q1 2021 was Citadel Advisors, an estimated $126K sold.

Based on aggregated 13F filings for Q1 2021.